The global primary cells market is likely to touch USD 1,233.67 million at an 8.13% CAGR between 2019- 2025, according to the recent Market Research Future (MRFR) report. Primary cells are directly isolated from blood cells or normal human tissue through the mechanical or enzymatic method. It retains its fundamental cellular functions, thus it is increasingly used in cell-based research programs. These cells are of two types- animal primary cells and human primary cells. Some of its sources include muscle and skeletal cells, lung cells, liver cells, gastrointestinal cells, skin cells, and hematopoietic cells. Owing to its multiple benefits and alluring features, primary cells have wide applications in research institutes and pharmaceutical & biotechnology companies.
Various factors are adding to the global primary cells market share. These factors, as per the new MRFR report, include rising preference of primary cells in R&D to create new drugs, increasing research on stem cells and personalized therapies, rising healthcare expenditure, burgeoning need for monoclonal antibodies, increasing adoption of primary cells over cell lines, growing cancer research, and rapidly growing biopharmaceutical and biotechnology industries.
On the contrary, risk of contamination and high price of advanced primary cells are factors that may limit the global primary cells market growth.
Key Players
Eminent players profiled in the global primary cells market report include Thermo Fisher Scientific Inc. (US), Zen Bio, Inc. (Research Triangle Park, NC), STEMCELL Technologies Inc. (Canada), Promo Cell (UK), Merck KGaA (Germany), Lonza Group, AG (Switzerland), Cell Biologics, Inc. (Chicago), Axol Bioscience Ltd (UK), American Type Culture Collection (ATCC) (Virginia), and All Cells (US). Industry players have encompassed strategies such as strategic alliances, contracts, new product launches, geographical expansions, mergers and acquisitions, research and development, mergers and acquisitions, and collaborations to create a niche in the market.
Market Segmentation
The MRFR report provides an inclusive segmental analysis of the global primary cells market based on Source, Type, and End user.
- By Source, the global primary cells market is segmented into muscle and skeletal cells, lung cells, liver cells, gastrointestinal cells, skin cells, and hematopoietic cells.
- By Type, the global primary cells market is segmented into animal primary cells and human primary cells.
- By End user, the global primary cells market is segmented into research institutes and pharmaceutical & biotechnology companies.
Regional Analysis
Based on the region, the global primary cells market covers the recent trends and growth opportunities across Europe, the Americas, the Asia Pacific (APAC), and the Middle East and Africa (MEA). Of these, the Americas will command the largest share in the market over the forecast period. Factors fuelling the market growth include increasing government funding and research, technological advancements, and growing prevalence of cancer. Besides, a huge patient pool suffering from cancer and rising healthcare expenditure by government organizations to offer a better life to people is also adding market growth.
The global primary cells market in Europe is predicted to hold the second-largest share over the forecast period. Factors propelling the market growth include the presence of developed economies such as France, the UK, and Germany, increasing cases of lifestyle-associated conditions, and favorable government laws and initiatives. Besides, increased investments in R&D activities are also adding market growth.
The global primary cells market in the APAC region is predicted to grow at a quick pace during the forecast period. The developing healthcare sector in Australia, India, Japan, and China, growing geriatric population, and rising per capita health spending are adding market growth.
The global primary cells market in the MEA is predicted to have the smallest share over the forecast period for the limited access to treatment facilities. Meanwhile, increasing expenditure by healthcare companies in Saudi Arabia coupled with new product launches, are likely to boost the market growth.
